Clinical trial
Phase 2, Randomized, Double-Blind, Multiple-Dose Level, Placebo Controlled, Single Intravenous Dose, Parallel Efficacy and Safety Study of NRX-1074 in Subjects With Major Depressive Disorder
NCT02067793 is registered in ClinicalTrials.gov with Naurex, Inc, an affiliate of Allergan plc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2, Randomized, Double-Blind, Multiple-Dose Level, Placebo Controlled, Single Intravenous Dose, Parallel Efficacy and Safety Study of NRX-1074 in Subjects With Major Depressive Disorder
- Lead sponsor
- Naurex, Inc, an affiliate of Allergan plc
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 31, 2014
- Completion date
- February 28, 2015
- Enrollment
- 151 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.